Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (405)	12/22/1997 11:10:00 PM
From: Brander	Read Replies (1) \| Respond to of 834

Bill, you said that "The FDA has nothing to do with this one way or the other." What about this: "TBC (TXB) submitted a new drug application (''NDA'') to the U.S. Food and Drug Administration (''FDA'') for NOVASTAN(R) as anticoagulant therapy in patients with heparin-induced thrombocytopenia (''HIT''), which was accepted during October. The FDA granted priority review status to the NDA, and the Company anticipates a decision on the approval of the NDA during the first half of 1998. If TXB was a scam company, do you really think the FDA would grant their drug priority review status? Brad